BLAINJECTIONINJECTABLEPriority Review
Approved
Feb 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIMIZIM (elosulfase alfa) is a recombinant hydrolytic enzyme replacement therapy administered by intravenous injection. It is indicated for Mucopolysaccharidosis IVa (Morquio A syndrome), a rare lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfatase enzyme. The drug works by replacing the deficient enzyme to break down accumulated glycosaminoglycans in lysosomes.
$0.017BPart D
PeakProduct is in peak commercialization phase with modest Part D spending, suggesting a stable but limited rare disease franchise with established patient base and mature sales infrastructure.
Mechanism of Action
Pharmacologic Class:
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIMIZIM offers deep expertise in rare disease commercialization, payer negotiation, and patient registry management—highly transferable skills in the expanding rare/ultra-rare pharma sector. The mature peak-stage product provides stable employment but limited growth trajectory, making it ideal for candidates seeking specialized domain knowledge rather than rapid career scaling.
Rare Disease Brand Manager
Worked on VIMIZIM at BioMarin Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.